LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
| Autor: | Moore, K.N., Bookman, M., Sehouli, J., Miller, A., Anderson, C., Scambia, G., Myers, T., Taskiran, C., Robison, K., Maenpaa, J., Willmott, L.J., Colombo, N., Thomes-Pepin, J., Gold, M.A., Aghajanian, C., Wu, F., Molinero, L., Khor, V., Lin, Y.G., Pignata, S. |
|---|---|
| Zdroj: | In Annals of Oncology September 2020 31 Supplement 4:S1161-S1162 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|